Radiation dose response for supratentorial XXXX --institutional experience and literature review.

@entity1 @entity66 @entity1161 @entity5 @entity11 @entity816 @entity3271
PURPOSE: To examine radiation dose response for @entity11 ( @entity11 ) based on our institutional experience and to review the literature on this topic. METHODS AND MATERIALS: Sixty-seven @entity1 with supratentorial low-grade nonpilocytic @entity816 (n=36) or @entity3271 (n=31) were treated with postoperative @entity1161 ( @entity1161 ). Twenty-seven @entity1 (group A) received 5520 cGy; 24 @entity1 (group B) received 5940 cGy; and 16 @entity1 (group C) received 6375 cGy. The corresponding median follow-up was 60, 35 and 91 months, respectively. RESULTS: The @entity66 ( @entity66 ) at 5 and 10 years were 90.2% and 56.2%, 67.6% and 47.3%, and 62.5% and 50% for groups A, B and C, respectively (P=0.40). Only a greater extent of surgical resection and absence of contrast enhancement predicted @entity66 on multivariate analyses. @entity1 receiving higher doses of @entity1161 had higher complication rates. CONCLUSION: Our data confirmed the lack of radiation dose response for supratentorial @entity11 as demonstrated in the previous randomized trials. The radiation dose should not exceed 5520 cGy because dose escalation did not result in an improvement of @entity66 and it also increased the complication rates. Future research should focus on the eradication of radioresistant clones either by the improvement of surgical resection or the use of cytotoxic agents that can target on the radioresistant @entity5 cells.
